Studies from Optum Inc. in the Area of Prostate Cancer Described [Real-world Utilization, Patient Characteristics, and Treatment Patterns Among Men With Localized Prostate Cancer Tested With the 17-gene Genomic Prostate Score(R) (Gps) Assay].
In: Cancer Weekly, 2024-05-21, S. 1123-1123
serialPeriodical
Zugriff:
A recent study conducted by Optum Inc. in Eden Prairie, Minnesota examined the utilization and characteristics of men with localized prostate cancer who were tested with the 17-gene Genomic Prostate Score (GPS) assay. The study found that the majority of men underwent active surveillance (AS) rather than definitive therapy (DT), and that AS decreased as the GPS result and National Comprehensive Cancer Network (NCCN) risk increased. The study suggests that the GPS assay can complement NCCN risk stratification in informing clinical management. The research was peer-reviewed and published in The Prostate journal. [Extracted from the article]
Copyright of Cancer Weekly is the property of NewsRx and its content may not be copied or emailed to multiple sites or posted to a listserv without the copyright holder's express written permission. However, users may print, download, or email articles for individual use. This abstract may be abridged. No warranty is given about the accuracy of the copy. Users should refer to the original published version of the material for the full abstract. (Copyright applies to all Abstracts.)
Titel: |
Studies from Optum Inc. in the Area of Prostate Cancer Described [Real-world Utilization, Patient Characteristics, and Treatment Patterns Among Men With Localized Prostate Cancer Tested With the 17-gene Genomic Prostate Score(R) (Gps) Assay].
|
---|---|
Zeitschrift: | Cancer Weekly, 2024-05-21, S. 1123-1123 |
Veröffentlichung: | 2024 |
Medientyp: | serialPeriodical |
ISSN: | 1071-7218 (print) |
Sonstiges: |
|